Open AccessThe effect of aromatase inhibitors on infertile men and its relation to sexual desire
Author(s) -
Ahmed Ali Mohammed Keshk,
Mohamed Farid Roaiah,
Alaa Mohammed Abdel-Moneam,
Amr Tharwat Alahwany,
Shady Zaki
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns2.5080
Subject(s) - aromatase , libido , testosterone (patch) , estrogen , medicine , aromatase inhibitor , mood , endocrinology , sexual desire , secondary sex characteristic , human sexuality , psychology , physiology , hormone , psychiatry , gender studies , cancer , sociology , breast cancer
Background: Aromatase inhibitors (AI) can boost endogenous testosterone production without increasing circulating estrogen levels, as shown with estrogen receptor modulators, Aim and Objectives: The study's goal was to determine the efficacy of aromatase inhibitor medication in improving spermatogenesis in oligozoospemic and azoospermic males, as well as its relationship to sexuality. Subjects and methods: This study was done on eighty man subjects joining the outpatient clinic of Andrology, Kasr El Aini Hospital, Cairo University during the peroid from April 2018 – April 2020, and they were divided into (2) groups, 40 subjects in each group. Results: There was a statistically significant difference in serum total testosterone measured before and after treatment in normal FSH patients with a p value ≤ 0.05. There was a notably not important change in sexual desire questionnaire measured before and after treatment in normal FSH patients with a p value > 0.05, Conclusion: ERs and aromatase share topographic sites in the brain with pheromones, indicating that estrogen influences both early sexual maturation and sexual behavior in adults. Estrogen can maintain libido while also influencing the number of serotonin receptors in the brain, which modulates mood, mental state, cognition, and emotion.